Geron Corporation met Q1 earnings expectations, with analysts rating it a "Moderate Buy" at $5.68 target.
Geron Corporation, a biopharmaceutical firm developing treatments for blood cancers, reported Q1 earnings meeting analyst expectations of ($0.04) EPS with $47.54M in revenue. Analysts have adjusted their ratings and price targets, resulting in a "Moderate Buy" consensus and a target price of $5.68. Institutional investors own 73.71% of the stock, valued at a market cap of $1.05 billion. Geron's lead drug, imetelstat, is in Phase 3 trials.
1 month ago
6 Articles
Articles
Further Reading
You have 6 free stories remaining this month. Subscribe anytime for unlimited access.